Equity Profile

BEAM

Beam Therapeutics Inc.

Health CareBiotechnology$3.2B

Mar14Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

Clinical Trial Progress

Updates on clinical trials are crucial as they indicate the advancement of Beam's therapies and their potential market readiness.

Updates on at least two ongoing trials.

Cash Burn Rate

Understanding the cash burn rate helps investors gauge the company's financial health and sustainability until it reaches profitability.

Expected to be around $50 million.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BEAM Q2-2026 Earnings Preview

Context

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. This innovative approach has the potential to treat a range of genetic diseases, making it a significant player in the health care sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

In the last quarter, Beam reported an EPS of -$0.91, slightly missing analyst expectations. The stock reacted negatively, declining by 2.69% the following day.

Management Promises & Guidance

Management committed to advancing clinical trials for their lead product candidates.
They emphasized the importance of securing additional funding to support ongoing research.
Management indicated plans to enhance their collaboration with academic institutions.

Expectations

Wall Street Expectations

Wall Street is cautiously optimistic about Beam's upcoming earnings, particularly regarding clinical trial updates and financial sustainability. However, the recent mixed performance raises concerns about the company's ability to meet expectations.

Bull Case

If Beam can demonstrate significant progress in its clinical trials and secure new partnerships, it could lead to a strong positive reaction from investors.

Bear Case

On the other hand, if the company fails to provide clear updates on its trials or shows a higher-than-expected cash burn, it could lead to further declines in stock price.

Key Metrics to Watch

Clinical Trial Progress

Updates on at least two ongoing trials.

Updates on clinical trials are crucial as they indicate the advancement of Beam's therapies and their potential market readiness.

Cash Burn Rate

Expected to be around $50 million.

Understanding the cash burn rate helps investors gauge the company's financial health and sustainability until it reaches profitability.

Partnership Announcements

At least one new partnership announcement.

New partnerships can enhance Beam's research capabilities and financial resources, impacting future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of their clinical trials?

Investors will closely watch for any advancements that could signal the potential for future revenue and market impact.

How does Beam plan to manage its cash burn rate moving forward?

Given the company's financial position, clarity on cash management will be critical for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Beam's potential for significant clinical trial advancements, which could lead to unexpected positive outcomes.

Supporting Evidence

The options market is pricing a 10.21% move, indicating expectations of volatility that may not align with historical performance.

Beam's recent partnerships and collaborations could provide a stronger foundation for future growth than currently acknowledged.

Key Risk

If clinical trial updates reveal promising results, it could shift the narrative dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on Beam's ability to balance clinical progress with financial sustainability.

Bull Confirmed If

Demonstrating a significant advancement in at least two clinical trials could validate the bull case.

Bear Confirmed If

A cash burn rate exceeding $50 million without clear funding strategies would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.21%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±10.2% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

74.1%

Calls (99K)P/C Ratio: 0.03Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations with positive trial updates, history suggests a potential stock increase of around 2.09%, confirming bullish sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess.

Miss

Should Beam miss expectations, the stock could decline by about 7.50%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of ongoing clinical trials and any new data.
2Updates on cash management strategies and funding plans.
3Information about potential new partnerships or collaborations.
4Insights into the competitive landscape and how Beam plans to differentiate itself.
5Any commentary on regulatory progress or challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

GitLab Inc.

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

Clinical Trial Progress

Updates on clinical trials are crucial as they indicate the advancement of Beam's therapies and their potential market readiness.

Updates on at least two ongoing trials.

Cash Burn Rate

Understanding the cash burn rate helps investors gauge the company's financial health and sustainability until it reaches profitability.

Expected to be around $50 million.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BEAM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

In the last quarter, Beam reported an EPS of -$0.91, slightly missing analyst expectations. The stock reacted negatively, declining by 2.69% the following day.

Management Promises & Guidance

Management committed to advancing clinical trials for their lead product candidates.
They emphasized the importance of securing additional funding to support ongoing research.
Management indicated plans to enhance their collaboration with academic institutions.

Expectations

Wall Street Expectations

Bull Case

If Beam can demonstrate significant progress in its clinical trials and secure new partnerships, it could lead to a strong positive reaction from investors.

Bear Case

On the other hand, if the company fails to provide clear updates on its trials or shows a higher-than-expected cash burn, it could lead to further declines in stock price.

Key Metrics to Watch

Clinical Trial Progress

Updates on at least two ongoing trials.

Updates on clinical trials are crucial as they indicate the advancement of Beam's therapies and their potential market readiness.

Cash Burn Rate

Expected to be around $50 million.

Understanding the cash burn rate helps investors gauge the company's financial health and sustainability until it reaches profitability.

Partnership Announcements

At least one new partnership announcement.

New partnerships can enhance Beam's research capabilities and financial resources, impacting future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of their clinical trials?

Investors will closely watch for any advancements that could signal the potential for future revenue and market impact.

How does Beam plan to manage its cash burn rate moving forward?

Given the company's financial position, clarity on cash management will be critical for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Beam's potential for significant clinical trial advancements, which could lead to unexpected positive outcomes.

Supporting Evidence

The options market is pricing a 10.21% move, indicating expectations of volatility that may not align with historical performance.

Beam's recent partnerships and collaborations could provide a stronger foundation for future growth than currently acknowledged.

Key Risk

If clinical trial updates reveal promising results, it could shift the narrative dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on Beam's ability to balance clinical progress with financial sustainability.

Bull Confirmed If

Demonstrating a significant advancement in at least two clinical trials could validate the bull case.

Bear Confirmed If

A cash burn rate exceeding $50 million without clear funding strategies would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.21%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±10.2% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

74.1%

Calls (99K)P/C Ratio: 0.03Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations with positive trial updates, history suggests a potential stock increase of around 2.09%, confirming bullish sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess.

Miss

Should Beam miss expectations, the stock could decline by about 7.50%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of ongoing clinical trials and any new data.
2Updates on cash management strategies and funding plans.
3Information about potential new partnerships or collaborations.
4Insights into the competitive landscape and how Beam plans to differentiate itself.
5Any commentary on regulatory progress or challenges.